Trial · NCT02417961
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home | Benra 30 mg | Week 12 | 112 | Participants | |
| Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home | Benra 30 mg | Week 16 | 108 | Participants | |
| Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home | Benra 30 mg | Weeks 12 and 16 | 106 | Participants | |
| Number and Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional | Benra 30 mg | Week 12 | 113 | Participants | |
| Number and Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional | Benra 30 mg | Week 16 | 108 | Participants | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 0 | 0 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 4 | 1 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 8 | 0 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 12 | 0 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 16 | 0 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 0 to 8 | 1 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 12 to 16 | 0 | Accessorized Pre-filled Syringe | |
| Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints) | Benra 30 mg | Week 0 to 16 | 1 | Accessorized Pre-filled Syringe | |
| The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score | Benra 30 mg | Week 4 | -0.53 | Standard Deviation 0.71 | Scores on a scale |
| The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score | Benra 30 mg | Week 8 | -0.54 | Standard Deviation 0.80 | Scores on a scale |
| The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score | Benra 30 mg | Week 12 | -0.72 | Standard Deviation 0.86 | Scores on a scale |
| The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score | Benra 30 mg | Week 16 | -0.82 | Standard Deviation 0.87 | Scores on a scale |
| The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score | Benra 30 mg | Week 20 | -0.73 | Standard Deviation 0.93 | Scores on a scale |
| The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab | Benra 30 mg | Baseline | NA | Geometric Coefficient of Variation NA | ng/mL |
| The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab | Benra 30 mg | Week 8 | 1031.644 | Geometric Coefficient of Variation 53.547 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02417961/results